LEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS
Open Access
- 15 June 2026
- journal article
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (2) , 7-13
Abstract
Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases. Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA). Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases. Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.Keywords
This publication has 25 references indexed in Scilit:
- Dabrafenib Inhibits Egr‐1‐Mediated Adhesion of Thyroid Cancer Cells to Pulmonary Microvascular EndotheliumJournal of Biochemical and Molecular Toxicology, 2024
- The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasisCellular & Molecular Immunology, 2023
- MCP-1: Function, regulation, and involvement in diseaseInternational Immunopharmacology, 2021
- IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2Toxicology and Applied Pharmacology, 2020
- MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasisOncogene, 2019
- MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasisBreast Cancer Research and Treatment, 2018
- The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironmentsCytokine, 2017
- Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1Breast Cancer Research and Treatment, 2015
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976